This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in ...
Treatment well tolerated with a safety profile consistent with standard-of-care (SoC) Increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline Continuous improvement of acromegaly symptom ...
MUMBAI, Aug 17 (Reuters) - Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the U.S. Food and Drug Administration to make and market octreotide injection, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback